Psoríase eritrodérmica refratária em criança com excelente resposta ao etanercepte

Fraga, Naiara A.; Paim, Maria de Fátima; Follador, Ivonise; Ramos, Andréia Nogueira; Rêgo, Vitória Regina Pedreira de Almeida

doi:10.1590/s0365-05962011000700038

Cited by 18 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was then stopped for ineffective results, after a total of ten injections [ 100 ]. Frega et al, however, reported the case of a 7-year-old patient suffering from erythrodermic psoriasis refractory to cyclosporine and methotrexate, responsive to etanercept [ 101 ].…”

Section: Biologic Drugsmentioning

confidence: 99%

Systemic Treatment of Pediatric Psoriasis: A Review

Napolitano

Megna

Balato

et al. 2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1–3% of the white population. Although the existence of two psoriasis incidence peaks has been suggested (one in adolescence before 20 years of age and another in adulthood), its onset may occur at any age, including childhood and adolescence, in which the incidence is now estimated at 40.8 per 100,000. As for adult psoriasis, pediatric psoriasis has recently been associated with obesity, metabolic syndrome, increased waist circumference percentiles and metabolic laboratory abnormalities, warranting early monitoring and lifestyle modifications. In addition, due to psoriasis' chronic nature and frequently occurring relapses, psoriatic patients tend to have an impaired quality of life, often requiring long-term treatment. Therefore, education of both pediatric patients and their parents is essential to successful and safe disease management. Given the lack of officially approved therapies, the very limited evidence-based data from randomized controlled trials, and the absence of standardized guidelines, to date, pediatric psoriasis treatment is primarily based on published case reports, case series, guidelines for adult psoriasis, expert opinions and experience with these drugs in other pediatric disorders coming from the disciplines of rheumatology, gastroenterology and oncology. This review focuses on the use of systemic treatments in pediatric psoriasis and their specific features, analyzing the few literature evidences available, expanding the treatment repertoire and guiding dermatologists in better managing of recalcitrant pediatric psoriasis.

show abstract

Section: Biologic Drugsmentioning

confidence: 99%

Systemic Treatment of Pediatric Psoriasis: A Review

Napolitano

Megna

Balato

et al. 2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Tumor Necrosis Factor (TNF) Antagonist Etanercept Etanercept, a recombinant human fusion protein, has demonstrated efficacy in treating EP. [49][50][51][52][53][54] Esposito et al reported that with 25 mg twice weekly, a treatment response could be observed between week 12-24. 49 At week 12, five of ten (50%) patients achieved PASI 75, and at week 24, six of ten (60%) patients achieved or maintained PASI 75, and two of ten patients (20%) maintained improvement between PASI 50 and PASI 75.…”

Section: Mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

show abstract

“…One of these patients was even continued on maintenance therapy for 2 years with lasting remission. 10 , 19 , 64 …”

Section: Systemic Agentsmentioning

confidence: 99%

“… 43 , 68 Methotrexate has been combined with several other agents for the treatment of EP, including with infliximab 55 , 69 – 71 ; with etretinate reporting satisfactory results 72 ; and with cyclosporine or etanercept reporting excellent results. 64 , 73 …”

Section: Systemic Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Erythrodermic psoriasis: pathophysiology and current treatment perspectives

Singh¹,

Lee²,

Uçmak³

et al. 2016

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare and severe variant of psoriasis vulgaris, with an estimated prevalence of 1%–2.25% among psoriatic patients. The condition presents with distinct histopathologic and clinical findings, which include a generalized inflammatory erythema involving at least 75% of the body surface area. The pathogenesis of EP is not well understood; however, several studies suggest that the disease is associated with a predominantly T helper 2 (Th2) phenotype. Given the morbidity and potential mortality associated with the condition, there is a need for a better understanding of its pathophysiology. The management of EP begins with a comprehensive assessment of the patient's presentation and often requires multidisciplinary supportive measures. In 2010, the medical board of the US National Psoriasis Foundation published consensus guidelines advocating the use of cyclosporine or infliximab as first-line therapy in unstable cases, with acitretin and methotrexate reserved for more stable cases. Since the time of that publication, additional information regarding the efficacy of newer agents has emerged. We review the latest data with regard to the treatment of EP, which includes biologic therapies such as ustekinumab and ixekizumab.

show abstract

Psoríase eritrodérmica refratária em criança com excelente resposta ao etanercepte

Cited by 18 publications

References 13 publications

Systemic Treatment of Pediatric Psoriasis: A Review

Systemic Treatment of Pediatric Psoriasis: A Review

Updates on the Treatment of Erythrodermic Psoriasis

Erythrodermic psoriasis: pathophysiology and current treatment perspectives

Contact Info

Product

Resources

About